Provinces Await Health Canada Approval Before Generic Coverage

Provincial Coverage Decisions on Hold

Provincial health ministries have informed insurance industry stakeholders they will not make coverage determinations for generic versions of Ozempic and Wegovy until Health Canada completes its regulatory review process. This position affects potential public drug plan access for millions of Canadians once generic alternatives become available.

The federal Non-Insured Health Benefits program, which covers First Nations and Inuit populations, is among the government programs taking a wait-and-see approach to generic semaglutide coverage policies.

Health Canada Review Timeline

Health Canada is currently reviewing nine generic semaglutide applications under its 180-day scientific review timeline. The generic semaglutide tracker shows submissions from manufacturers including Sandoz Canada, Apotex, Teva Canada, and others submitted following the January 4, 2026 patent expiration.

Industry experts anticipate at least one or two approvals by spring 2026, with additional approvals expected throughout the remainder of the year. The regulatory review timeline means provincial coverage decisions will likely follow Health Canada approvals by several months.

Insurance Industry Implications

The provincial stance creates a sequential approval process where regulatory approval precedes coverage determination. This approach may delay public access to lower-cost generic alternatives even after Health Canada grants market authorization.

Private insurance plans and employer drug benefits may have more flexibility to establish coverage policies independent of provincial decisions. Many private insurers are already evaluating how generic semaglutide will fit into their formulary structures and cost management strategies.

Coverage Policy Framework

Provincial drug plans typically evaluate new medications through health technology assessment processes that consider clinical evidence, cost-effectiveness, and budget impact. Generic semaglutide applications will likely undergo similar evaluations once regulatory approval is secured.

The coverage evaluation process examines:

• Therapeutic equivalence to brand-name versions
• Cost savings potential for public drug budgets
• Patient access criteria and coverage conditions
• Prior authorization requirements

Market Access Timeline

The sequential approval approach means Canadians seeking public coverage for generic alternatives to Mounjaro and other GLP-1 medications may face extended wait times beyond the initial Health Canada approval dates.

Healthcare providers and patients can monitor coverage developments through provincial drug plan updates and the insurance coverage checker as policies evolve throughout 2026.

Next Steps for Coverage Decisions

Provincial health ministries will begin their coverage evaluation processes once Health Canada issues Notices of Compliance for generic semaglutide products. The timing of these provincial decisions will determine when generic alternatives become accessible through public drug plans.

Additional information about coverage policies and approval timelines is available in the FAQ section as developments unfold.